The study was to evaluate the safety and effectiveness of ultrasound-guided percutaneous laser ablation (pLA) as a nonsurgical treatment for primary @entity3243 . Surgery was contraindicated in, or refused by, the included @entity1 . No lesion enhancement on contrast-enhanced ultrasound immediately after pLA was considered "complete ablation." Nodule size, serum @entity460 , and parathyroid hormone level were compared before and after pLA. Complete ablation was achieved in all 21 @entity1 with 1 (n = 20) or 2 (n = 1) sessions. Nodule volume decreased from 0.93    0.58   mL at baseline to 0.53    0.38 and 0.48    0.34   mL at 6 and 12 months after pLA (P < 0.05). At 1 day, 6 months, and 12 months after pLA, serum @entity461 decreased from 15.23    3.00   pmol/L at baseline to 7.41    2.79, 6.95    1.78, and 6.90    1.46   pmol/L, serum @entity460 decreased from 3.77    0.77   mmol/L at baseline to 2.50    0.72, 2.41    0.37, and 2.28    0.26   mmol/L, respectively (P < 0.05). At 12 months, treatment success (normalization of @entity461 and serum @entity460 ) was achieved in 81%. No serious complications were observed. Ultrasound-guided pLA with contrast-enhanced ultrasound is a viable alternative to surgery for primary @entity3243 .

Percutaneous Ultrasound-Guided Laser Ablation with Contrast-Enhanced Ultrasonography for Hyperfunctioning XXXX : A Preliminary Case Series.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3243 :: ('MESH:D010282', 'Disease') :: ['parathyroid adenoma'] @entity461 :: ('5741', 'Gene') :: ['PTH'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']
@entity3243 :: (MESH:D010282,Disease) :: ['Parathyroid Adenoma']
